Validated using a knockout cell lineRecombinantRabMAb

Recombinant HRP Anti-MEK2 antibody [Y78] (ab200607)

Submit a review Submit a question
Western blot - HRP Anti-MEK2 antibody [Y78] (ab200607)
  • Western blot - HRP Anti-MEK2 antibody [Y78] (ab200607)
  • HRP Anti-MEK2 antibody [Y78] (ab200607)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • HRP Rabbit monoclonal [Y78] to MEK2
  • Suitable for: WB
  • Knockout validated
  • Reacts with: Human
  • Conjugation: HRP

Conjugates logo Related conjugates and formulations

Alexa Fluor® 488 Alexa Fluor® 555 Alexa Fluor® 594 Alexa Fluor® 647 Carrier Free PE Unconjugated

Overview

  • Product name

    HRP Anti-MEK2 antibody [Y78]
    See all MEK2 primary antibodies

  • Description

    HRP Rabbit monoclonal [Y78] to MEK2

  • Host species

    Rabbit

  • Conjugation

    HRP

  • Tested applications

    Suitable for: WBmore details

  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: Jurkat whole cell lysate.

  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab200607 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
1/7500. Detects a band of approximately 45 kDa (predicted molecular weight: 44 kDa).
Notes
WB
1/7500. Detects a band of approximately 45 kDa (predicted molecular weight: 44 kDa).

Target

  • Function

    Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.

  • Involvement in disease

    Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.

  • Sequence similarities

    Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.

  • Post-translational
    modifications

    MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
    Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt

  • Database links

    • Alternative names

      • Cardiofaciocutaneous syndrome antibody
      • CFC syndrome antibody
      • CFC4 antibody
      • Dual specificity mitogen activated protein kinase kinase 2 antibody
      • Dual specificity mitogen-activated protein kinase kinase 2 antibody
      • ERK activator kinase 2 antibody
      • FLJ26075 antibody
      • MAP kinase kinase 2 antibody
      • map2k2 antibody
      • MAPK / ERK kinase 2 antibody
      • MAPK/ERK kinase 2 antibody
      • MAPKK 2 antibody
      • MAPKK2 antibody
      • MEK 2 antibody
      • MEK2 antibody
      • Microtubule associated protein kinase kinase 2 antibody
      • Mitogen activated protein kinase kinase 2 antibody
      • Mitogen activated protein kinase kinase 2 p45 antibody
      • MKK 2 antibody
      • MKK2 antibody
      • MP2K2_HUMAN antibody
      • OTTHUMP00000165826 antibody
      • OTTHUMP00000165827 antibody
      • PRKMK 2 antibody
      • PRKMK2 antibody
      see all

    Images

    • Western blot - HRP Anti-MEK2 antibody [Y78] (ab200607)
      Western blot - HRP Anti-MEK2 antibody [Y78] (ab200607)
      All lanes : HRP Anti-MEK2 antibody [Y78] (ab200607) at 1/7500 dilution

      Lane 1 : Wild-type HAP1 whole cell lysate
      Lane 2 : MAP2K2 (MEK2) knockout HAP1 whole cell lysate

      Lysates/proteins at 20 µg per lane.

      Predicted band size: 44 kDa
      Observed band size: 44 kDa


      Exposure time: 30 seconds


      ab200607 was shown to specifically react with MEK2 in wild-type HAP1 cells as signal was lost in MAP2K2 (MEK2) knockout cells. Wild-type and MAP2K2 (MEK2) knockout samples were subjected to SDS-PAGE. Ab200607 and ab184095 (Mouse monoclonal [mAbcam 9484] to GAPDH - Loading Control (Alexa Fluor® 680) loading control) were incubated overnight at 4°C at 1/7500 dilution and 1/1000 dilution respectively. The loading control was imaged using the Licor Odyssey CLx prior to blots being developed with ECL technique.

    • Western blot - HRP Anti-MEK2 antibody [Y78] (ab200607)
      Western blot - HRP Anti-MEK2 antibody [Y78] (ab200607)
      HRP Anti-MEK2 antibody [Y78] (ab200607) at 1/7500 dilution + Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg

      Developed using the ECL technique.

      Performed under reducing conditions.

      Predicted band size: 44 kDa
      Observed band size: 45 kDa why is the actual band size different from the predicted?
      Additional bands at: 100 kDa. We are unsure as to the identity of these extra bands.


      Exposure time: 10 seconds


      This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab200607 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

    • HRP Anti-MEK2 antibody [Y78] (ab200607)
      HRP Anti-MEK2 antibody [Y78] (ab200607)

    References (0)

    Publishing research using ab200607? Please let us know so that we can cite the reference in this datasheet.

    ab200607 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab200607.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com